Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Keros Therapeutics Inc (NASDAQ: KROS) closed at $11.01 in the last session, up 0.64% from day before closing price of $10.94. In other words, the price has increased by $0.64 from its previous closing price. On the day, 1.08 million shares were traded.
Ratios:
We take a closer look at KROS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 21.45 and its Current Ratio is at 21.45. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On January 17, 2025, Wedbush Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $15.
Oppenheimer reiterated its Outperform rating for the stock on December 16, 2024, while the target price for the stock was revised from $102 to $63.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 125.63 while its Price-to-Book (P/B) ratio in mrq is 0.78.
Stock Price History:
Over the past 52 weeks, KROS has reached a high of $73.00, while it has fallen to a 52-week low of $9.77. The 50-Day Moving Average of the stock is -15.79%, while the 200-Day Moving Average is calculated to be -74.38%.
Shares Statistics:
A total of 40.55M shares are outstanding, with a floating share count of 32.83M. Insiders hold about 18.96% of the company’s shares, while institutions hold 79.02% stake in the company.
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Keros Therapeutics Inc (KROS) in the stock market.The consensus estimate for the next quarter is -$1.39, with high estimates of -$1.39 and low estimates of -$1.4.
Analysts are recommending an EPS of between -$5.36 and -$5.7 for the fiscal current year, implying an average EPS of -$5.53. EPS for the following year is -$4.03, with 7.0 analysts recommending between -$2.25 and -$6.02.
